Buprenorphine Initiatives and Capacity Analysis in Maryland
|
|
- Neal Barnett
- 5 years ago
- Views:
Transcription
1 Buprenorphine Initiatives and Capacity Analysis in Maryland B. Casey Lyons, MPH Department of Health and Mental Hygiene Presented to: PDMP East Regional Meeting October 25, 2016 Preliminary Data DO NOT CITE
2 Overview What is Buprenorphine? Maryland Buprenorphine initiatives Buprenorphine capacity Maryland specific methodology and results SAMHSA Region 3 assessment proposal
3 Buprenorphine Overview Partial opioid agonist FDA approved for use in pain management FDA approved for use in treatment of opioid use disorder Federal regulations under DATA2000 control prescribing for OUD treatment Must have special DEA DATA-waiver to prescribe for OUD Original patient panel caps at 30 and 100, for physicians only Caps changed earlier this summer now three levels: 30, 100 and 275 New rules also expand prescribing to NPs and PAs Concerns over access for OUD treatment due to greater restrictions
4 Maryland Buprenorphine Access Projects Goals: Increase number of DATA-waivered prescribers in currently underserved populations /geography Increase cap level at which prescribers waivered Support providers to prescribe up to their cap Current Initiatives: Gap buprenorphine prescribing in emergency departments Pilot program in Baltimore City PCSS-MAT
5 Buprenorphine Capacity Assessment using PDMP Data First run last year, repeating this year Initial activity: Aim to estimate the current capacity of buprenorphine prescribing in the state Known caveats OTPs and prescriber (office-based) dispensing of bupe for OUD not required to report to PDMP, so will be underestimate of true prescribing In MD, PAs and NPs may also prescribe with proper licensing Veterinarians prescribe buprenorphine and report to PDMP
6 Data Sources Buprenorphine: queries conducted in vendor portal Specific brand names and formulations of drugs designated as either for pain or for OUD treatment after review of FDA indication on drug labels Pain: Belbuca, Buprenex, Butrans, injectable generic buprenorphine OUD: Bunavail, Butrans, Probuphine, Suboxone, Subutex, Zubsolv, generic buprenorphine tablets and all generic buprenorphine/naloxone formulations ***DATA2000 prohibits prescribing formulations indicated for pain relief for OUD treatment, but does not restrict off-label prescribing of formulations indicated for OUD treatment to relieve pain*** Prescribers: DEA DATA-waiver information obtained from DEA Registrant File PDMP prescriber information obtained from vendor portal Crosslinked information using SAS and Excel
7 Results: Buprenorphine Dispensed in Maryland to Recipients at Maryland Addresses Buprenorphine Prescriptions by Type, Jan 1- Oct 15, 2016 OUD 97% PAIN 3% DRUG NAME/FORMULATION RX COUNT % TOTAL BELBUCA BUNAVAIL BUPRENEX BUPERENORPHINE-NALOXONE BUPRENORPHINE VIAL BUPRENORPHINE TABLETS BUPRENORPHINE POWDER BUTRANS PROBUPHINE SUBOXONE FILM SUBOXONE TABLET ZUBSOLV Total Highlighted rows = pain management formulations Source: MD PDMP, October 17, 2016
8 Results: Initial Prescriber Counts DEA FILE Number %total PDMP Number %total Pain OUD Both 150 Total Prescribers 2578 Prescribers are those who wrote at least one prescription that was dispensed in Maryland to someone with a Maryland address Total Practitioners DW/ DW/ Military DW/ Military DW/100 0 DOD Contractor DW/30 0 DOD Contractor DW/100 0 DW/ Military DW/275 0 DOD Contractor DW/275 0 Total DW *Preliminary data DO NOT CITE Source: MD PDMP+ DEA Registrant Database, October 17, 2016
9 Merge Process Initial match of PDMP Prescriber and DEA Registrant files on DEA Number Hand matching of X-codes based on name/address Noted additional potential matches based on name with unique DEA numbers these have not been reconciled in this analysis Hand matching of a few records missing a waiver type but with Maryland addresses (meant that DEA Number in PDMP was not in initial waiver status coding based on DEA registrant file) Matching of PDMP Pain and OUD Prescriber subsets to intermediate file on DEA Number and then on X-code Final hand matching to ensure each record had either pain or OUD designation
10 Results: Final Prescriber Counts *Preliminary data DO NOT CITE Merge %Merge %DEA File Number total total MD DW MD Not DW Other Total DEA Waiver No %total Original DEA Types Match Match Total Match File DW/ DW/ Military DW/ DW/ Total Source: Analysis of Merged File, October 20, 2016
11 Results: Prescriber Characteristics DW 275 2% Unable to Match 6% Prescribers by Waiver Status In State, Not DW 38% DW % Out Of State Address 26% DW 30 15% Waiver Type Pain SUD Both Total DW DW DW Out Of State Address Unable to Match In State, Not DW *Preliminary data DO NOT CITE Source: Analysis of Merged File, October 20, 2016
12 Takeaways Only ~3.5% of MD practitioners have a data waiver Bulk of buprenorphine dispensed to MD residents year to date were formulations for OUD Almost all of DW/275 practitioners prescribed, specifically for OUD; only 47.5% of DW/30 prescribed in past year, though most for OUD ~41% of non-dw prescribers wrote at least one script for a OUD formulation Majority of out of state prescribing for OUD as well
13 Data Challenges Prescription side: Created rule for pain vs. SUD on indication, not on known use (diagnosis) Missing anything dispensed in office/otp because not required to report to PDMP Reports prescription count, not individual recipients Unable to characterize dose escalation vs maintenance prescriptions Prescriber side: Out of state prescribers (per address linked to DEA number) higher than anticipated Matching multiple DEA numbers/practices to same individual: 74 possible in/out of state matches, 44 possible within state, 19 possible both out of state X-coded DEA numbers difficult to match Poor data quality in PDMP unmatchable DEA numbers, missing names
14 Other States in Data Set 34 states represented by at least one prescriber record Top 10 includes all our border states who are also our SAMHSA Region 3 partners! *Preliminary data DO NOT CITE State Prescriber Count PA 139 VA 126 DC 73 DE 44 FL 25 NJ 23 NY 21 WV 20 CA 8 NC 8 Source: Analysis of Merged File, October 20, 2016
15 SAMHSA Region 3 Proposal Primary Goal: most feasible, initial dive into data Describe the current volume of office-based physician buprenorphine prescribing and patient utilization within contiguous states, including: number of active buprenorphine prescribers, stratified by waiver status (100 patient, 30 patient or no waiver) number of patients currently being prescribed buprenorphine by physicians, stratified by physician waiver status Physician prescribing and patient utilization activity at the jurisdictional and sub-jurisdictional level, particularly in state border areas Draft Proposal, April 2016
16 SAMHSA Region 3 Proposal Secondary Goals: more complex to address due to resources or data limitations, but provides truly actionable results Determining rates of physician prescribing and patient utilization based on the physician density and general populations in geographic area Identifying the specialty status of active physician buprenorphine prescribers Estimating the gap between current service availability and actual need at the regional, state, jurisdictional or sub-jurisdictional level through analysis of data on deaths, hospitalizations, specialty treatment admissions and other potential indicators of opioid addiction prevalence.
17 Current Status Activities to date: Region III calls, including TA from Chris Jones who is working with PBSS states on similar analysis Regional partners filled out surveys regarding data access and state law/policies regarding data collection (i.e. reporting) and linkage Excitement around idea Partners recognize fluidity of patient movement within region and need for regional assessment SAMHSA interest in support; similar project being conducted by PBSS Next Steps Start with analyses intra-state, then consider linking across states? Obtain input from others who might be doing this kind of work?
18 Potential Barriers to Overcome Identified Barriers Lack of staffing and/or staff hours for analysis Access to applicable data files (PDMP, DEA/SAMHSA, etc) Technical capacity for cleaning and linking data Differences between states in how unique prescribers and patients identified in PDMP dataset (e.g. use of X-DEA numbers, patient matching or clustering) Legal restrictions around data sharing of identifiable data variables, even for public health use Others?? How do we overcome these barriers?
19 Acknowledgements Office of Overdose Prevention Michael Baier Brian Holler Kate Jackson Behavioral Health Administration Kathy Rebbert-Franklin Christy Trenton SAMHSA Region 3 Jean Bennett Contact Info: Michael Baier, Director, Overdose Prevention michael.baier@maryland.gov Phone: Casey Lyons, Overdose Prevention Epidemiologist brianna.lyons@maryland.gov Phone: TTAC Pat Knue Jim Giglio
BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES
BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES BACKGROUND In September 2012, the Division of Medicaid (DOM) implemented criteria through electronic prior authorization (PA)
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationMapping Opioid and Other Drug Issues (MOODI) Tool. Washington State Category 3 Grant BJA Meeting August 2016
Mapping Opioid and Other Drug Issues (MOODI) Tool Washington State Category 3 Grant BJA Meeting August 2016 MOODI A statewide GIS mapping tool that integrates PDMP and other opioid-related datasets to
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
More informationPublic Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
More informationClinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.
Clinical Policy: (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: 09.01.17 Last Review Date: 02.18 Line of Business: Medicaid See Important Reminder at the end of this policy for
More informationUSE OF BUPRENORPHINE FOR CHRONIC PAIN
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationThe Latest Prescription Trends for Controlled Prescription Drugs
The Latest Prescription Trends for Controlled Prescription Drugs September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner
More informationPolicy and Political Dynamics of the Opioid Addiction Crisis in the United States
Policy and Political Dynamics of the Opioid Addiction Crisis in the United States Mark W. Parrino, M.P.A. July 21, 2018 15 th Annual Midwest Conference on Problem Gambling and Substance Abuse Hilton Kansas
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationSC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC
SC MAT ACCESS Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC Overdose Death Rates from Opiates Most important sign of a
More informationPDMP Track: Linking and Mapping PDMP Data. Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health
PDMP Track: Linking and Mapping PDMP Data Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health Disclosure Statement Gillian Leichtling and Chris Baumgartner have disclosed no
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationCorporate Medical Policy
Corporate Medical Policy Buprenorphine Implant for Treatment of Opioid Dependence File Name: Origination: Last CAP Review: Next CAP Review: Last Review: buprenorphine_implant_for_treatment_of_opioid_dependence
More informationClinical Policy: Buprenorphine-Naloxone (Suboxone, Bunavail, Zubsolv) Reference Number: CP.PMN.XX. Line of Business: Medicaid
Clinical Policy: (Suboxone, Bunavail, Zubsolv) Reference Number: CP.PMN.XX Effective Date: 09/17 Last Review Date: 08/17 Line of Business: Medicaid See Important Reminder at the end of this policy for
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationAddressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
More informationAbuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions
Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions Eric Lavonas, MD, FACEP, FACMT, FAACT Associate Director, Rocky Mountain Poison & Drug Center Denver
More informationOverdose Survivors Outreach Program (OSOP)
Overdose Survivors Outreach Program (OSOP) Brian Holler, MPH Special Programs Manager Office of Overdose Preventions Behavioral Health Administration Department of Health and Mental Hygiene Background
More informationBuprenorphine addiction
Buprenorphine addiction Search 16-11-2013 High hopes for buprenorphine, an effective treatment for opioid addiction, have been tempered by a messy reality: health complications and deaths. The ATTC Network
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationTreatment Gaps in Opioid-Agonist Medication Assisted Therapy (OA-MAT) in California Counties: How Many Additional Prescribers Are Needed?
Treatment Gaps in Opioid-Agonist Medication Assisted Therapy (OA-MAT) in California Counties: How Many Additional Prescribers Are Needed? Lisa Clemans-Cope, Marni Epstein, Doug Wissoker (Urban Institute)
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationAssessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources
Assessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources NPN Conference Anaheim, CA September 12, 2017 Presentations Overview of SAMHSA s Prevention
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Probuphine, Sublocade) Reference Number: CP.PHAR.289 Effective Date: 11.16.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationOpioid Treatment in North Carolina SEPTEMBER 13, 2016
Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained
More informationTHA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
More informationPrescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD
Prescribing Opioids in the Opioid Epidemic Scott Woffinden, PA-C Jason Chapman, JD What's the Problem? http://www.zdoggmd.com/blank-script-taylor-swift-parody/ What's the Problem? CDC 115 Americans die
More informationOpioid Overview Admiral Brett P. Giroir, M.D.
A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE
More informationStatus of Opioid Treatment Efforts
Status of Opioid Treatment Efforts Health Reform Oversight Committee October 25, 2016 Harry Chen, MD, Commissioner The National Safety Council Categorized Vermont as One of Four States Making Progress
More informationThe Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country
Integrating Primary and Behavioral Health Care Through the Lens of Prevention July 14, 2016 New Orleans, Louisiana The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationPrescription Monitoring Program. One Agency s Experience. Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA
Prescription Monitoring Program One Agency s Experience Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA Agency Description Private non-profit, founded 1973 $8.5 M annual budget; staff
More informationRI Centers of Excellence for the
RI Centers of Excellence for the Treatment of Opioid Use Disorder COE CODAC Behavioral Healthcare Linda Hurley President/CEO 9-18-17 for the Warren Alpert Medical School of Brown University RI s Strategic
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationDear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good
PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion
More informationFrom Medicaid Transformation Approved Project Toolkit, June 2017
From Medicaid Transformation Approved Project Toolkit, June 2017 Domain 3: Prevention and Health Promotion Transformation projects within this domain focus on prevention and health promotion to eliminate
More informationGoToWebinar Housekeeping: Attendee participation
GoToWebinar Housekeeping: Attendee participation Your Participation Join audio: Choose Mic & Speakers to use your computer for audio. Not recommended for desktop units but works with laptops If not using
More informationAddressing the Opioid Crisis An ACH Collaboration
Addressing the Opioid Crisis An ACH Collaboration The purpose of this document is to offer a set of strategies that can help hospitals, health systems, and independent/group practices and Accountable Communities
More informationHarold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD
Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD National Epidemic Highlighted numerous studies/media reports State Epidemic Highlighted
More informationUsing Telehealth to Provide Medication-Assisted Treatment for Opioid Disorders
Using Telehealth to Provide Medication-Assisted Treatment for Opioid Disorders 1 October 5, 2017 Robert Stephens, Health Officer, Garrett County Health Department Eric Weintraub, M.D., Department of Psychiatry,
More informationAddressing the Opioid Crisis Policy Recommendations
Addressing the Opioid Crisis Policy Recommendations The Pew Charitable Trusts Pew is an independent nonprofit, nonpartisan research and policy organization. Tools: Research Partnerships Technical assistance
More informationSTATE TARGETED RESPONSE TO THE OPIOID CRISIS (OPIOID STR)
STATE TARGETED RESPONSE TO THE OPIOID CRISIS (OPIOID STR) September 26, 2017 Kimberly A. Johnson, PhD, Director, Center for Substance Abuse Treatment, SAMHSA Donna Hillman, GPO and Opioid STR CSAT Project
More informationSANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery
Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018
More informationRecommendations for Components of Emergency Department Discharge Protocols
Recommendations for Components of Emergency Department Discharge Protocols Background Maryland, like many other states, is in the midst of an opioid crisis. In 2016, 89 percent of all intoxication deaths
More informationCDC s Approach to Addressing the Opioid Overdose Epidemic
CDC s Approach to Addressing the Opioid Overdose Epidemic Sarah Bacon National Center for Injury Prevention and Control Division of Unintentional Injury Prevention June 23, 2016 500,000 drug overdose deaths
More informationProject Nurture Collaborative. Alison Noice, MA CADC-III Christy Hall Helen Bellanca, MD, MPH
Project Nurture Collaborative Alison Noice, MA CADC-III Christy Hall Helen Bellanca, MD, MPH Disclosures No disclosures Direct Care Provider (SUD, physical health) Who s in the Room Today? Administrator
More information9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)
9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More information14th Annual Maryland Patient Safety Conference Medication-Assisted Treatment: A Priority Response to Maryland s Overdose Crisis
14th Annual Maryland Patient Safety Conference Medication-Assisted Treatment: A Priority Response to Maryland s Overdose Crisis Kathleen Rebbert-Franklin, LCSW-C Behavioral Health Administration (BHA)
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationWhat is the strategy?
What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health
More informationThe CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
More informationMission: The Oregon Coalition for Responsible Use of Meds (OrCRM) is a Statewide Coalition launched to prevent overdose, misuse and abuse of
Mission: The Oregon Coalition for Responsible Use of Meds (OrCRM) is a Statewide Coalition launched to prevent overdose, misuse and abuse of amphetamines and opioids, both prescription and illicit, among
More informationMobilizing a Response to the Opioid Epidemic: County Snapshots. Kelly Pfeifer, MD May 10, 2018
Mobilizing a Response to the Opioid Epidemic: County Snapshots Kelly Pfeifer, MD kpfeifer@chcf.org May 10, 2018 Housekeeping All lines are muted This session will be recorded To ask a question: Questions
More informationQUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.
2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted
More informationPRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationCOMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Jan 1, 2018)
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Jan 1, 2018) Provider Type 32: Opioid Treatment Program H0001 Alcohol and/or Drug Assessment $147.74 Per assessment H0004 Individual Outpatient
More informationCOMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017)
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017) Provider Type 32: Opioid Treatment Program Service Description Rate Unit Service Limits Combination of Service Rules H0001 Alcohol
More informationADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE
ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE Matthew Keats, MD, MMM Behavioral Health Medical Director Virginia Department of Medical Assistance Services October 26, 2017 www.dmas.virginia.gov
More information8/16/2018. California s MAT Expansion Hub and Spoke System: Provider and Consumer Perspectives. Agenda. No Wrong Door
California s MAT Expansion Hub and Spoke System: Provider and Consumer Perspectives Gloria Miele, PhD, Learning Collaborative Coordinator, Hub and Spoke MAT Expansion Project Richard Rawson, PhD, Professor
More informationArwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationUsing the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices
Using the NC Controlled Substances Reporting System to Identify Providers Manifesting Unusual Prescribing Practices Prevention Research Center Penn State December 2, 2015 Chris Ringwalt, DrPH* Sharon Schiro,
More informationOctober 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies
October 20, 2016 Scott K. Proescholdbell, MPH Opioid Overdose and North Carolina s Public Health and Prevention Strategies Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury,
More informationMedicaid Treatment and Service Fees for Substance Use Disorder (SUD): CY
Medicaid Treatment and Service Fees for Substance Use Disorder (SUD): CY 2012 2016 A Chart Book March 22, 2018 Abridged Version Prepared for the Maryland Department of Health TABLE OF CONTENTS Chapter
More informationPolicy Evaluation: Substance Use Disorders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationExpanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital
Expanding Access To Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital August 28, 2018 Hosted by John A. Renner, Jr., MD, DLFAPA Professor of Psychiatry Boston University
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationCOMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017)
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017) Provider Type 32: Opioid Treatment Program Service Description Rate Unit Service Limits Combination of Service Rules H0001 Alcohol
More informationDaniel Blaney-Koen, JD July 2018
National overview: America s opioid epidemic Daniel Blaney-Koen, JD July 2018 National landscape AMA Opioid Task Force Policy efforts Barriers to care Reasons for optimism 2 Illicit fentanyl and heroin
More informationBuprenorphine Prescribing as a Patient- Centered Medical Home Enhancement
Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement TANNER NISSLY DO, BOB LEVY MD FASAM, MICHELE MANDRICH MSW, CMPE AS YOU ENTER, PLEASE SET UP TO PARTICIPATE IN OUR POLL EVERYWHERE
More informationCOMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2018) Provider Type 32: Opioid Treatment Program
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2018) Provider Type 32: Opioid Treatment Program H0001 Alcohol and/or Drug Assessment $152.91 Per assessment H0004 Individual Outpatient
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 4: Overdose Survivors Outreach Project October 18, 2017 Agenda Overdose Survivors Outreach Project (OSOP) Background Barry Page, Director of Early
More informationThe Opioid Crisis Made in America Fade in America?
The Opioid Crisis Made in America Fade in America? The President s Commission On Combating Drug Addiction and the Opioid Crisis Bertha K Madras, PhD Professor of Psychobiology Department of Psychiatry
More informationOverdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine.
Part B 2 3 4 Overdose Treatment Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Specifically used to counteract lifethreatening depression of
More informationAGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
More informationU.S. SURGEON GENERAL, VIVEK MURTHY MD
FORMER U.S. SURGEON GENERAL, VIVEK MURTHY MD AN ESTIMATED 20.8 MILLION PEOPLE IN OUR COUNTRY ARE LIVING WITH A SUBSTANCE USE DISORDER. THIS IS SIMILAR TO THE NUMBER OF PEOPLE WHO HAVE DIABETES, AND 1.5
More informationBUPRENORPHINE (PROBUPHINE & SUBLOCADE )
UnitedHealthcare Oxford Clinical Policy BUPRENORPHINE (PROBUPHINE & SUBLOCADE ) Policy Number: PHARMACY 291.5 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationMassachusetts Responds to the Opioid Epidemic Using Data To Inform Policy and Programs. Monica Bharel, MD MPH Commissioner of Public Health
Massachusetts Responds to the Opioid Epidemic Using Data To Inform Policy and Programs Monica Bharel, MD MPH Commissioner of Public Health Data For Massachusetts 2017 Q2 Quarterly Report and Chapter 55
More informationOverview and Findings from ASTHO s IIS Interstate Data Sharing Meeting
Overview and Findings from ASTHO s IIS Interstate Data Sharing Meeting Kim Martin Association of State and Territorial Health Officials (ASTHO) May 12, 2015 The Need for IIS Interstate Data Exchange States,
More informationNational Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders
National Academies of Sciences, Engineering, and Medicine Forum on Neuroscience and Nervous System Disorders Workshop: Advancing Therapeutic Development for Pain and Opioid Use Disorders through Public-Private
More informationMaryland Medicaid and Opioid Epidemic
Maryland Medicaid and Opioid Epidemic Sara Cherico Senior Health Policy Analyst Office of the Secretary Maryland Department of Health and Mental Hygiene June 23, 2016 National Opioid Addiction and Overdose
More informationPreventing opioid poisonings Presenting responsible pain management Promoting Substance Use Treatment and Support services
Preventing opioid poisonings Presenting responsible pain management Promoting Substance Use Treatment and Support services Fred Wells Brason II fbrason@projectlazarus.org Pilot Project Setting Manual labor
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #468 (NQF 3175): Continuity of Pharmacotherapy for Opioid Use Disorder (OUD) National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention and Treatment of Opioid
More informationCOMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff May 15, 2017)
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff May 15, 2017) Provider Type 32: Opioid Treatment Program Procedure Code Service Description Rate Unit Service Limits H0001 Alcohol and/or Drug Assessment
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More information